Role of angiogenesis in chronic lymphocytic leukemia

Cancer

Volumn 107, Issue 5, 2006, Pages 925-934

  Letilovic, Tomislav ^a   Vrhovac, Radovan ^a   Verstovsek, Srdan ^b   Jaksic, Branimir ^a   Ferrajoli, Alessandra ^b  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Angiogenic factors; Chronic lymphocytic leukemia; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOSTATIC PROTEIN; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; BIOLOGICAL MARKER; CATENIN; CD31 ANTIGEN; CYTOKINE; ENDOSTATIN; FLAVOPIRIDOL; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MATRIX METALLOPROTEINASE; PLACENTAL GROWTH FACTOR; PLASMINOGEN; PLATELET DERIVED GROWTH FACTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RESTIN; SCATTER FACTOR; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; CYTOKINES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 33747891840     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22086     Document Type: Review

References (85)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
2. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757-1763.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
4. Arora B, Mesa RA, Tefferi A. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma. 2004;45:2373-2386.
5. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-20.
6. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-2642.
7. Mesa RA, Hanson CA, Li CY, et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood. 2002;99:4131-4137.
8. Risau W, Sariola H, Zerwes HG, et al. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development. 1988;102:471-478.
9. Ellis LM, Liu W, Ahmad SA, et al. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol. 2001;28:94-104.
10. Pepper MS. Role of matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Atheroscler Thromb Vasc Biol. 2001;21:1104-1117.
11. Brew K, Dinakarpadian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267-283.
12. Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of VE cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 1999;98:147-157.
13. Fox SB. Tumor angiogenesis and prognosis. Histopathology. 1997;30:294-301.
14. Weidner N, Semple JP, Welsch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
15. Weidner N. Intratumor vessel density as a prognostic factor in cancer. Am J Pathol. 1995;147:9-19.
16. Bostwick DG, Wheeler TM, Blute M, et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996;48:47-57.
17. Chang YS, di Tomaso E, McDonald DM, Jones M, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 2000;97:14608-14613.
18. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med. 2001;7:987-989.
19. Weber WA, Haubner R, Vabuliene E, Kuhnast B, Wester HJ, Schwaiger M. Tumor angiogenesis targeting using imaging agents. Q J Nucl Med. 2001;45:179-182.
20. Baglin TP, Crocker J, Timmin A, Chandler S, Boughton BJ. Bone marrow hypervascularity in patients with myelofibrosis identified by infrared thermography. Clin Lab Haematol. 1991;13:341-348.
21. Dirix LY, Vermeulen PB, Pawinski A, et al. Elevated levels of angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer. 1997;76:238-243.
22. Banks RE, Forbes MA, Kinsey SE, et al. Release of angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998;77:956-964.
23. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003;63:3121-3126.
24. Perkins GD, Roberts J, McAuley DF, et al. Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury. Thorax. 2005;60:153-158.
25. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science. 1985;228:1324-1326.
26. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001;97:3658-3661.
27. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood. 2006;107:2531-2535.
28. Wierzbowska A, Robak T, Krawczynska A, et al. Circulating endothelial cells in patients with acute myeloid leukemia. Eur J Haematol. 2005;75:492-497.
29. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001;61:4341-4344.
30. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
31. Fink SR, Paternoster SF, Smoley SA, et al. Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia. Leuk Res. 2005;29:253-262.
32. Jaksic O, Vrhovac R, Kusec R, et al. Clinical tumor cell distribution pattern is a prognostically relevant parameter in patients with B-cell chronic lymphocytic leukemia. Haematologica. 2001;86:827-836.
33. Ribatti D, Vacca A, De Falco G, Ria R, Roncali L, Damacco F. Role of hematopoietic growth factors in angiogenesis. Acta Haematol. 2001;106:157-161.
34. Bertolini F, Mancuso P, Gobbi A, Pruneri G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol. 2000;28:993-1000.
35. Krejci P, Dvorakova D, Krahulcova E. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemia. Leukemia. 2001;15:228-237.
36. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia. 2005;19:513-523.
37. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD 154 on CLL cells. Leukemia. 2005;19:524-530.
38. Gabrilove JL. Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies. Oncologist. 2001;6:4-7.
39. Bairey O, Zimra Y, Shaklai M, Rabizadeh E. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. B J Haemat. 2001;113:400-406.
40. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin 6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630-2636.
41. Kini AR, Kay NE, Peterson LE. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000;14:1414-1418.
42. Till KJ, Spiller DG, Harris RJ, Chen H, Zuzel M, Cawley JC. CLL, but not normal, B cells are dependent on autocrine VEGF and {alpha}4{beta}1 integrin for chemokine-induced motility on and through endothelium. Blood. 2005;105:4813-4819.
43. Jaksic O, Paro MM, Kardum Skelin I, Kusec R, Pejsa V, Jaksic B. CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood. 2004;103:1968-1969.
44. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter receptor of CD31, an Ig superfamily member. J Immunol. 1998;160:395-402.
45. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood. 2003;102:2146-2155.
46. Peterson LC, Kini AR, Kay NE. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood. 2001;97:2529.
47. Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 2002:3344-3351.
48. Molica S, Vacca A, Levato D, Merchionne F, Ribbati D. Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res. 2004;28:321-324.
49. Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000;96:3181-3187.
50. Duensing S, Atzpodien J. Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood. 1995;85:1978-1980.
51. Gora-Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators Inflamm. 2003;12:167-171.
52. Menzel T, Rahman Z, Calleja E, et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic leukemia and is associated with resistance to fludarabine. Blood. 1996;87:1056-1063.
53. Konig A, Menzel T, Lynen S, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia. 1997;11:258-265.
54. Kay NE, Bone ND, Tschumper RC, et al. B-CLL cells are capable of synthesis and secretion of both pro- and antiangiogenic molecules. Leukemia. 2002;16:911-919.
55. Gora-Tybor J, Blonski JZ, Robak T. Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia. Neoplasma. 2002;49:145-148.
56. Molica S, Vitelli G, Levato D, Ricciotti A, Digiesi G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer. 2002;86:31-35.
57. Aguayo A, O'Brien S, Keating M. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96:768-770.
58. Fett JW, Strydom DJ, Lobb RR, et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985;24:5480-5486.
59. Soncin F. Angiogenin supports endothelial and fibroblast cell adhesion. Proc Natl Acad Sci USA, 1992;89:2232-2236.
60. Distler JW, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003;47:149-161.
61. Molica S, Vitelli G, Levato D, et al. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. Eur J Haematol. 2004;73:36-42.
62. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res. 2004;28:243-248.
63. Kay NE. The angiogenic status of B-CLL B cells: role of the VEGF receptors. Leuk Res. 2004;28:221-222.
64. Ferrajoli A, Manshouri T, Estrov Z, et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001;7:795-799.
65. Aguayo A, Manshouri T, O'Brien S, et al. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res. 2001;25:279-285.
66. Bauvois B, Dumont J, Mathinot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia. 2002;16:791-798.
67. Kamiguti AS, Lee ES, Till KJ, et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukemia. Br J Haematol. 2004;125:128-140.
68. Molica S, Vitelli G, Levato D, et al. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol. 2003;70:373-378.
69. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-407.
70. Shimizu K, Oku N. Cancer antiangiogenic therapy. Biol Pharm Bull. 2004;27:599-605.
71. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet. 2001;357:539-545.
72. Barton JC. Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia. Am J Hematol. 2003;74:205-207.
73. Chanan-Khan A, Miller KC, Takeshita K, et al. Results of phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 2005;106:3348-3352.
74. Chanan-Khan AA, Miller KC, Marshall P, et al. Thalidomide (T) in combination with fludarabine (F) as initial therapy for patients (pts) with treatment naive chronic lymphocytic leukemia (CLL): preliminary results of a phase I/II clinical trial. Blood. 2005;106:834a.
75. Chanan-Khan AA, Miller KC, DiMiceli L, et al. Results of phase II study of lenalidomide (L) (Revlimid®) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2005;106:135a.
76. Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of antiproliferative, proapoptotic and anti-angiogenic effects. Oncogene. 1999;18:7514-7526.
77. Marzo I, Perez-Galan P, Giraldo P, et al. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-CLL chronic lymphocytic leukemia cells. Leukemia. 2004;18:1599-1604.
78. Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs. 2004;15:411-419.
79. Pepper C, Thomas A, Hoy T, Fegan C, Bentley P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2001;114:70-77.
80. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocitic leukemia via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p-53. Blood. 1998;92:3804-3816.
81. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11:4176-4181.
82. Flin IW, Byrd JC, Bartlett N, et al. Flavopiridol administered as 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005;29:1253-1257.
83. Lin TS, Fischer B, Moran ME, et al. Flavopiridol, fludarabine and rituximab is a highly active regimen in indolent B-cell lymphoproliferative disorders including mantle cell lymphoma. Blood. 2005;106:278a.
84. Shanafelt TD, Greyer S, Bone N, et al. Evaluation of the prognostic implications of pro- and anti-angiogenic cytokines in 311 patients with untreated chronic lymphocytic leukemia. Blood. 2005;106:211a.
85. Aboudola S, Kini AR. Angiogenesis in lymphoproliferative disorders: a therapeutic target? Curr Opin Hematol. 2005;12:279-283.